Travoprost
CAS No:
157283-68-6
Molecular Formula：
C26H35F3O6
Molecular Weight：
500.55
Storage:
Store in a tightly closed container in a cool, dry，Protect from moisture and direct sunlight.
Download Product Documents
If documents are missing, please contact customer service.
Technical Data
| Appearance | Colorless or pale yellow oil |
|---|---|
| Identification | By TLC:The Travoprost should be appear as Black Spots. |
| Specific rotation | [a]D20:+52°~+58°(20mg/ml,Etoh,365nm) |
| Water | ≤ 1.0% |
| RelatedSubstances | Travoprost Related compound A≤ 0.2% |
| Residual sovents | Isopropanol ≤ 0.5% |
| Assay | 96%~102%(anhydrous and solvent free basis) |
Description
Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin analog (or more specifically, an analog of prostaglandin F2α) that works by increasing the outflow of aqueous fluid from the eyes.
Safety Information
GHS
Pictogram:
Signal Word:
Danger
Hazard Statements:
May be harmful if inhaled
May cause cancer
Highly flammable liquid and vapor
Precautionary Statements:
Obtain special instructions before use
Do not handle until all safety precautions have beenreadandunderstood
Use personal protective equipment as required
Keepawayfromheat/sparks/openflames/hotsurfaces.—Nosmoking
Keep container tightly closed
Ground/bond container and receiving equipment
Use only non-sparking tools
Take precautionary measures against static discharge
–
IF exposed or concerned: Get medical advice/attentionIF ON SKIN (or hair):
Remove/Take off immediately all
contaminated clothing. Rinse skin with water/shower
In case of fire: Use CO2, dry chemical, or foamfor extinction
–
Store locked up Store in a well-ventilated place. Keepcool
Dispose of contents/container to an approved wastedisposal
plant
References
- M R Hellberg, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001 Oct;17(5):421-32.
Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study. Sridharan K. BMC Ophthalmol. 2024 Dec 31;24(1):554. doi: 10.1186/s12886-024-03823-w. PMID: 39741235; PMCID: PMC11686995.
Travoprost Intracameral Implant: A Review on the Novel Treatment Modality for Open-Angle Glaucoma and Ocular Hypertension. Huston J, Paauw M, Orey D, Centner A, Hasan A, Shetty R, Freidl K, Goldfaden R. Ann Pharmacother. 2024 Dec 10:10600280241291911. doi: 10.1177/10600280241291911. Epub ahead of print. PMID: 39658880.
Changes in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study. Li W, Chen X, Chen S, Lv Z, Tang J, Li N. Cutan Ocul Toxicol. 2024 Dec 2:1-8. doi: 10.1080/15569527.2024.2431570. Epub ahead of print. PMID: 39620977.
Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS. Kim YK, Woo IS, Park CG, Kim A, Choi JD, Son KH, Han KM. J Chromatogr A. 2025 Jan 4;1739:465516. doi: 10.1016/j.chroma.2024.465516. Epub 2024 Nov 13. PMID: 39579545.
Restoration of Corneal Stiffness in Rabbits Following Withdrawal of Travoprost. Zheng X, Wang C, Fan Y, Hong Y, Bao H, Zhang E, Jin Y, Yang P, Li L, Wang J, Chen S, Elsheikh A, Bao F. Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):35. doi: 10.1167/iovs.65.13.35. PMID: 39546291; PMCID: PMC11580291.
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database. Wu SN, Huang C, Wang YQ, Li X, Zhang SQ, Chen XD, Qin DY, Zhu L, Wen JY, Luo NC, Hu J, Liu Z. Ther Adv Drug Saf. 2024 Oct 16;15:20420986241285929. doi: 10.1177/20420986241285929. PMID: 39429679; PMCID: PMC11487502.
Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography. Durmuş Ece BŞ, Yozgat Z, Bayramlı H, Ece B, Aydin S. J Clin Med. 2024 Sep 28;13(19):5808. doi: 10.3390/jcm13195808. PMID: 39407871; PMCID: PMC11478186.
Reviews
There are no reviews yet.